Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioelectronics's Enterprise Value is $7.41 Mil.
Bioelectronics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil. Therefore, Bioelectronics's EV-to-FCF for today is -48.95.
The historical rank and industry rank for Bioelectronics's EV-to-FCF or its related term are showing as below:
BIEL'
s EV-to-FCF Range Over the Past 10 Years
Min: -154.41 Med: 0 Max: 0
Current: -49.09
BIEL's EV-to-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 23.28
vs BIEL: -49.09
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioelectronics's PE Ratio (TTM) for today is calculated as:
Bioelectronics's share price for today is $0.0003.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioelectronics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioelectronics EV-to-FCF Related Terms
Bioelectronics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioelectronics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioelectronics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioelectronics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioelectronics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioelectronics's EV-to-FCF falls into.
Bioelectronics's current Enterprise Value is $7.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioelectronics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioelectronics (BIEL) has a EV-to-FCF of -48.95 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioelectronics and its competitors.
Is Bioelectronics' EV-to-FCF too high?
Bioelectronics' current EV-to-FCF is -48.95.
How does Bioelectronics' EV-to-FCF compare to NUVPF and ADMD?
Bioelectronics' EV-to-FCF of -48.95 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-FCF is 23.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.28, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioelectronics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioelectronics's current EV-to-FCF is -48.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioelectronics stock overvalued right now?
Bioelectronics (BIEL) has a current EV-to-FCF of -48.95. The current EV-to-FCF is -48.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioelectronics (BIEL), the current EV-to-FCF is -48.95 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioelectronics Corp is a US-based electroceutical company that develops wearable neuromodulation devices using pulsed electromagnetic field technology to relieve pain and support tissue recovery without drugs. Its product line includes ActiPatch for musculoskeletal pain, Allay for menstrual pain, RecoveryRx for postoperative and chronic wounds, and a smart insole for heel pain. The company sells through wholesale distributors, directly to hospitals and clinics, and to consumers, generating revenue from device sales across these channels. Its technology targets neurological and pain-related conditions, with a focus on non-invasive, drug-free treatment alternatives.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIEL has been successfully added to your 
